Pfizer Inc. (NYSE:PFE) Shares Bought by Claret Asset Management Corp

Claret Asset Management Corp grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 145.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 295,892 shares of the biopharmaceutical company's stock after buying an additional 175,273 shares during the quarter. Pfizer accounts for 1.2% of Claret Asset Management Corp's investment portfolio, making the stock its 22nd biggest position. Claret Asset Management Corp's holdings in Pfizer were worth $7,850,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Passumpsic Savings Bank increased its stake in shares of Pfizer by 8.4% in the third quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company's stock worth $743,000 after buying an additional 1,998 shares during the period. Virtu Financial LLC purchased a new stake in Pfizer in the 3rd quarter worth approximately $1,499,000. Westside Investment Management Inc. grew its position in shares of Pfizer by 7.7% in the 3rd quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company's stock worth $404,000 after buying an additional 1,004 shares during the last quarter. Diamant Asset Management Inc. lifted its stake in Pfizer by 8.4% in the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company's stock worth $246,000 after acquiring an additional 660 shares during the period. Finally, Morse Asset Management Inc bought a new stake in shares of Pfizer during the 3rd quarter valued at about $2,649,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on PFE. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday. They issued a "neutral" rating and a $24.00 price target on the stock. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, UBS Group decreased their price objective on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.57.

Pfizer Trading Down 0.5 %

NYSE PFE traded down $0.12 on Wednesday, hitting $22.41. 32,999,021 shares of the stock were exchanged, compared to its average volume of 40,426,858. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The firm has a market capitalization of $127.10 billion, a P/E ratio of 15.89, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a fifty day moving average price of $24.75 and a two-hundred day moving average price of $26.08.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 EPS. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.